How Do Pain and Spine Practices Market Within Compliance Lines?

Last updated: November 12, 2026 · By Kayce Sadler, Founder & CEO, Abode Marketing

Market what you can prove and what patients can verify: the conditions you evaluate, who your providers are and how they’re credentialed, how fast new patients can be seen, and plain education. Leave out success rates, recovery timelines, and “avoid surgery” promises unless you have the kind of evidence the FTC expects. Then run every piece through a short pre-publish check for testimonials, patient privacy, ad platform rules, and Louisiana’s board certification wording.

Which rules actually apply to a pain or spine practice’s marketing?

More than most owners realize, and they come from different places. At the federal level, the FTC polices deceptive health claims and fake or misleading testimonials. HIPAA governs any use of patient information in marketing. Google has its own healthcare advertising policies that can disapprove an ad or suspend an account. And in Louisiana, the medical practice act gives the Louisiana State Board of Medical Examiners grounds to discipline physicians for misleading advertising.

None of these is hard on its own. The trouble is that a single sentence on a landing page, like “90% of our patients avoid surgery,” can run into three of them at once.

What counts as an outcome claim, and why is it risky?

An outcome claim is anything that tells a patient what will happen to them: “get back to golf in six weeks,” “lasting relief without surgery,” “our patients reduce their pain medication.” If you can’t back it up with solid clinical evidence, it’s a problem.

The FTC’s Health Products Compliance Guidance, published in December 2022, says health benefit claims generally need “competent and reliable scientific evidence,” usually randomized, controlled human trials. It’s written about products, but I use it as the yardstick for any treatment claim because it shows how the FTC thinks about health evidence. The same guidance says testimonials and patient surveys are never enough on their own.

The FTC’s Endorsement Guides (16 CFR 255.2) add a second layer: when you feature one patient’s result, the audience reads it as what patients generally achieve. If that isn’t true, the testimonial itself is misleading.

Can we use patient testimonials or success stories at all?

Yes, with care. First, HIPAA: HHS’s marketing guidance says a covered entity needs the individual’s written authorization before using their protected health information for marketing. A testimonial video, a quote with a first name and a procedure, or a photo of a patient in your clinic all count. Get a separate, signed authorization and keep it on file.

Second, the FTC. The 2024 consumer review and testimonial rule (16 CFR Part 465, effective October 21, 2024) bans fake testimonials, buying reviews, offering perks conditioned on positive sentiment, and undisclosed reviews from staff or relatives. If a patient got anything of value, like a free visit, the connection has to be disclosed clearly.

Third, the story itself. Testimonials about the experience (“the front desk got me in within a week,” “Dr. X explained my MRI in plain English”) are far safer than testimonials about results.

What won’t Google Ads let a pain clinic advertise?

Google’s Healthcare and medicines policy is stricter than many clinics expect. A few lines that matter most for pain and spine practices:

• Opioids: “Google doesn’t allow ads promoting or selling prescription opioid painkillers,” with narrow exceptions such as certified addiction treatment providers. Google treats violations as egregious, which can mean suspension without warning.
• Regenerative treatments: Stem cell therapy, other cellular therapies, gene therapy, and platelet-rich plasma (PRP) fall under Google’s speculative and experimental treatment policy. In the U.S., only FDA-licensed or approved cell or gene therapies can be promoted, and only by the entity that holds that license or approval. Purely educational content is allowed.
• Prescription drug terms: Google restricts prescription drug names in ads, landing pages, and keywords.
• Addiction services: If part of your practice treats opioid use disorder, U.S. advertisers need LegitScript certification and then Google’s own certification before running those ads.

What does Louisiana’s medical board law add?

Two provisions in La. R.S. 37:1285 come up most in marketing reviews. Paragraph (A)(7) makes it grounds for discipline to solicit patients or self-promote through advertising or communication that is fraudulent, false, deceptive, or misleading.

Paragraph (A)(32) covers “board certified.” A physician can’t present themselves as certified by a board unless the ad includes the full name of the certifying board and the specialty or subspecialty, and the board is an American Board of Medical Specialties member board, an American Osteopathic Association certifying board, approved by the Louisiana State Board of Medical Examiners, or requires ACGME- or AOA-approved postgraduate training covering that field. Otherwise the ad must state the physician’s qualifications for the advertised procedures. “Board-certified pain doctor” on a billboard, with no board named, is the kind of line to fix.

The enforcement risk is real. In January 2025, the FTC announced federal court orders against the Stem Cell Institute of America, co-founded by two chiropractors, which trained clinics to market stem cell injections with false claims about osteoarthritis, neuropathy, and joint pain. The defendants were permanently barred from marketing regenerative treatments and ordered to pay $3,310,146 in refunds and $1,845,000 in civil penalties.

So what should a pain or spine practice market instead?

Plenty, and it tends to work better anyway. Patients choosing a pain or spine practice want to know whether you see their problem, who they’ll see, whether you take their insurance, and how soon they can get in.

• Condition pages that explain the condition, what an evaluation involves, and the range of options a provider may discuss, without promising which will work.
• Provider pages with training, board certification stated the Louisiana way, and the conditions each provider evaluates.
• Access details: locations, hours, how new-patient appointments work, insurance accepted, and whether a referral is needed.
• Education: what to bring to a first visit, how to read an imaging report, questions to ask about any procedure.

A pre-publish checklist for any page, ad, or post

1. Does it promise or imply a result, timeline, or percentage? If yes, is there clinical evidence we can produce? If not, cut it.
2. Does it feature a patient? Is there a signed HIPAA marketing authorization on file?
3. Does the testimonial describe a result? If so, would most patients get the same result? If not, rewrite around the experience.
4. Did the patient receive anything of value? Is that disclosed clearly?
5. Does it say “board certified”? Is the full board name and specialty included?
6. Does it mention PRP, stem cells, regenerative medicine, opioids, or a prescription drug by name? Check Google’s healthcare policy before it goes into an ad.
7. Does it say “permanent,” “safe,” “painless,” or “fixes it for good”? Remove or qualify it.
8. Was any of it drafted with AI? Has a clinician read it for accuracy?

What we’d check first

1. Your condition and procedure pages for percentages, timelines, and “avoid surgery” language, plus whether each page has a clear path to request a new-patient visit on mobile.
2. Your Google Business Profile services, description, and posts, since outcome language often hides there, and whether photos show patients without authorization.
3. Provider listings across directories for consistent names, credentials, and board certification wording.
4. Reviews and replies compared to the three practices in your map pack, including any replies that mention a patient’s care.
5. Google Ads: disapprovals, regenerative or prescription drug keywords, and who is bidding on your practice name.
6. AI answers: what ChatGPT and Google AI Overviews say when asked about pain management in your city, and whether they repeat old claims from your site. Check whether your ChatGPT business profile is claimed.

Related reading: our AI marketing guardrails for Louisiana medical practices, how we work with Louisiana medical practices, and how to set a medical practice marketing budget.

If you’d like a second set of eyes, our free visibility audit reviews your Google profile, reviews, listings, website, ads, and AI answers, and we’ll point out any claims that look worth a compliance review before you spend more promoting them.

More owner questions we’ve answered: Can My Practice Respond to a Negative Patient Review Under HIPAA? · Why Are Patients Choosing the Clinic Down the Street Instead of Mine? · How Do I Fix a Duplicate Google Business Profile?

Frequently asked questions

Can we say a treatment is FDA approved in our marketing?

Only if it’s accurate for the specific product and use you’re describing. The FTC’s case against the Stem Cell Institute of America included false claims about FDA approval of stem cell injections. If you’re unsure of a product’s regulatory status, leave the claim out and describe the procedure instead.

Is it okay to share before-and-after patient stories on social media?

Only with a signed HIPAA authorization for marketing use, and only if the story doesn’t imply a typical result you can’t support. Stories about access, communication, or the visit experience carry less risk than stories about recovery. A short internal sign-off by a clinician and your compliance lead helps.

Do Louisiana’s medical advertising rules apply to nurse practitioners and chiropractors in our practice?

R.S. 37:1285 governs physicians licensed by the Louisiana State Board of Medical Examiners, while other licensees answer to their own boards and practice acts. The FTC and HIPAA rules apply across the practice either way. Have each provider’s board rules reviewed before their bios and ads go live.

Can our pain practice run Google Ads at all?

Yes, for permitted services such as evaluations and treatments that aren’t restricted under Google’s healthcare policy. The issues usually come from opioid mentions, prescription drug terms, or regenerative treatments like PRP and stem cell therapy. Review Google’s Healthcare and medicines policy for each campaign before launch.

Sources

• FTC: Health Products Compliance Guidance (Dec 2022) — Competent and reliable scientific evidence; testimonials never sufficient; ‘results not typical’ doesn’t cure
• eCFR: 16 CFR Part 255, Endorsement Guides — 255.2(b) typical results; 255.5 material connections
• Federal Register: Trade Regulation Rule on the Use of Consumer Reviews and Testimonials — 16 CFR Part 465, effective Oct 21, 2024
• Google Ads Policy Help: Healthcare and medicines — Opioid painkiller ad ban, prescription drug term restrictions, addiction services certification
• Google Ads Policy Help: Speculative and experimental medical treatment, cell therapies, and gene therapies — Stem cell, cellular, gene therapy and PRP restricted; FDA-licensed exception; educational content allowed
• Louisiana Legislature: R.S. 37:1285 — (A)(7) misleading advertising; (A)(32) board certification advertising requirements
• FTC: Court orders against Stem Cell Institute of America co-founders (Jan 8, 2025) — False efficacy and FDA-approval claims; $3,310,146 refunds and $1,845,000 civil penalties